Skip to main content
Elsevier

Diagnosis and Management in Parkinson's Disease

The Neuroscience of Parkinson’s Disease, Volume 1

  • 1st Edition - August 13, 2020
  • Latest edition
  • Editors: Colin R. Martin, Victor R. Preedy
  • Language: English

Diagnosis and Management in Parkinson's Disease: The Neuroscience of Parkinson’s, Volume 1 provides a single source of material covering different scientific domains of neurop… Read more

Description

Diagnosis and Management in Parkinson's Disease: The Neuroscience of Parkinson’s, Volume 1 provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. It fills a much-needed gap as a "one-stop" synopsis of everything concerning the neurology and neuroscience related to Parkinson’s disease, from chemicals and cells to individuals. The book is an invaluable resource for neuroscientists, neurologists, and anyone in the field.

Key features

  • Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease
  • Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction
  • Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding
  • Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations
  • Serves as a "one-stop" source for everything you need to know about Parkinson’s disease

Readership

Neuroscientists/neurologists, psychologists, health scientists, public health workers, research scientists, pharmacologists, and physicians. Graduate/postgraduate students, lecturers, and professors

Table of contents

Part I: Introductory chapters and setting the scene

1. Progression of symptoms in Parkinson’s diseaseFederico Paolini Paoletti, Lucia Farotti and Lucilla Parnetti

2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson’s disease: an overviewK.F. Loewenbruck, F. Pan-Montojo and H. Reichmann

3. The role of environmental toxins and inflammation in Parkinson’s disease pathophysiology: a historical perspective and research-based evidenceF. Pan-Montojo, K.F. Loewenbruck and H. Reichmann

4. Environmental and genetic risk factors for Parkinson’s diseaseLazaros Belbasis, Vanesa Bellou and Evangelos Evangelou

5. Recent developments in the etiology, treatment, and potential therapeutic targets for Parkinson’s disease: a focus on biochemistrySapana Sameer Chaudhary, Sameer Chaudhary, Sakshi Rawat, Saieswari Natesan, Tanvee Pardeshi, Athanasios Alexiou and Ghulam Md Ashraf

6. Facial emotion recognition in Parkinson’s disease: methodological, clinical, and pathophysiological factorsMarco De Risi, Enrica Olivola, Giancarlo Di Gennaro and Nicola Modugno

7. Diurnal patterns and circadian aspects of Parkinson’s disease: retinal, hypothalamic/midbrain, and pineal participationGregory L. Willis

8. Parkinson’s disease and social mediaIbrahim S. Al-Busaidi and Yassar Alamri

9. Sleep disturbances in Parkinson’s diseasAdriano D.S. Targa, Juliane Fagotti, Patrícia Dominico, Ana Paula Chuproski and Marcelo M.S. Lima

10. Recurrent falls in people with Parkinson’s diseaseLorena Rosa S. Almeida, Serene S. Paul and Guilherme T. Valenca

11. Medical decision-making in patients with Parkinson’s diseaseJanneke Koerts, Josephien Jansen, Anselm B.M. Fuermaier, Lara Tucha and Oliver Tucha

12. Visual impairment in Parkinson’s diseaseAlessandro Arrigo, Alessandro Calamuneri, Emanuela Aragona, Enricomaria Mormina and Michele Gaeta

13. Autonomic problems in Parkinson’s disease: a focus on the bladderRyuji Sakakibara, Fuyuki Tateno, Tatsuya Yamamoto and Tomoyuki Uchiyama

14. Dementia and bladder dysfunction: a focus on treatments with anticholinergicsRyuji Sakakibara and Fuyuki Tateno

15. Linking and comparing non-motor symptoms in aging and Parkinson’s diseasePetra Bago Rozankovic

16. Progression of motor symptoms in Parkinson’s diseaseDaniela Vieira, Joana Jesus-Ribeiro and Cristina Januario

17. The stigma of Parkinson’s disease: development and implications John T.H. Tsiang and Benjamin K.P. Woo

Part II: Biomarkers, instruments, diagnosis and assessments

18. Better neuroradiological approach for the diagnosis of early-stage Parkinson’s disease patientsYasuaki Mizutani, Yoshiki Niimi and Tatsuro Mutoh

19. Use of positron-emission tomography as a diagnostic and differential diagnostic tool in parkinsonian syndromesPetra Tomse, Tomaz Rus, Matej Perovnik, Chris C. Tang, David Eidelberg and Maja Trost

20. Keyboard typing for the detection of early Parkinson’s diseaseWarwick R. Adams

21. Cerebrospinal fluid biomarkers of Parkinson’s disease: an updateKanae Nagao and Peter A. LeWitt

22. Understanding Parkinson’s disease pathophysiology: clinical application of eye movement tasks and underlying neural correlatesKikuro Fukushima, Junko Fukushima and Graham R. Barnes

23. Measuring quality of life in Parkinson’s diseaseMaria Jo~ao Forjaz, Carmen Rodríguez-Blazquez and Pablo MartinezeMartin

24. Clinically assessing cognitive function in Parkinson’s diseaseMegan Bakeberg, Maddeson Riley, Michelle Byrnes, Frank L. Mastaglia and Ryan S. Anderton

Part III: Pharmacological treatments, other agents and strategies

25. A new neuroprotective strategy for the drug therapy of Parkinson’s disease: Ca2þ/cAMP signaling as therapeutic targetsAfonso Caricati-Neto, Fulvio Alexandre Scorza and Leandro Bueno Bergantin

26. Dopamine agonists in treatment of Parkinson’s disease: an overviewDan Luo, Maarten Reith and Aloke K. Dutta

27. Management with apomorphine in Parkinson’s diseaseManon Auffret, Sophie Drapier and Marc Verin

28. Management with monoamine oxidase B inhibitors in Parkinson’s diseaseThomas Muller

29. Management with antibiotics in Parkinson’s diseaseMariza Bortolanza, Bruno L. Santos-Lobato, Glauce Crivelaro Nascimento and Elaine Del-Bel

30. Intracerebroventricular administration of dopamine in Parkinson’s disease: treatment of motor fluctuations and dyskinesiaC. Laloux, C. Lachaud, C. Moreau, M. Fisichella, J.C. Devedjian, J.A. Duce and D. Devos

31. Placebo and nocebo responses in Parkinson’s diseaseFabrizio Benedetti, Elisa Carlino, Elisa Frisaldi, Alessandro Piedimonte, Maurizio Zibetti, Michele Lanotte and Leonardo Lopiano

32. Levodopa-induced dyskinesias in Parkinson’s diseaseStephanie L. Alberico and Nandakumar S. Narayanan

33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s diseaseMiguel A. Abellanas and Maria S. Aymerich

Part IV: Non-pharmacological, novel and other treatment procedures

34. Deep brain stimulation surgery in Parkinson’s diseaseLee Neilson, Jonathan Zande and Hesham Abboud

35. Gene delivery for Parkinson’s diseasePiotr Chmielarz, Anne Panhelainen, Mikko Airavaara and Andrii Domanskyi

36. Cell transplantation therapy for Parkinson’s diseasePiotr Chmielarz, Julia Konovalova and Andrii Domanskyi

37. Ursodeoxycholic and tauroursodeoxycholic acids as antiapoptotic agents: modulation of Parkinson’s diseaseNoha F. Abdelkader

38. Interlinking potential therapy with botulinum neurotoxin-A and Parkinson’s diseaseAndreas Wree, Alexander Hawlitschka, Carsten Holzmann, Martin Witt, Jens Kurth, Tobias Lindner, Teresa Mann and Veronica Antipova

39. Neuropeptide cocaine- and amphetamine-regulated transcript usage in Parkinson’s diseasePeizhong Mao and Yifan Mao

40. Photobiomodulation as a neuroprotective strategy for Parkinson’s diseaseClaudia Petrucco, Patrick Benson, Luke Gordon, Jonathan Stone and Daniel M. Johnstone

41. Assistive technologies in Parkinson’s diseaseRoongroj Bhidayasiri

Index

Product details

  • Edition: 1
  • Latest edition
  • Published: September 18, 2020
  • Language: English

About the editors

CM

Colin R. Martin

Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, UK

VP

Victor R. Preedy

Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK; Visiting Professor, University of Hull, UK

View book on ScienceDirect

Read Diagnosis and Management in Parkinson's Disease on ScienceDirect